市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。
当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。
Emerging Pharmaceutical Markets Globally
世界の新興医薬品市場
新興国の医薬品市場における成長は、世界的な医薬品市場の全体的な成長を上回っています。この成長は、これらの国々における急速な経済成長、国民一人あたりの所得の向上、生活習慣病の有病者数の増加、および低価格要素によると考えられます。新興7カ国(ブラジル、ロシア、中国、インド、トルコ、メキシコ、およびインドネシア)における医薬品市場は、2008年に約960億USドルと見積もられ、これらの市場は、世界の医薬品市場におけるシェアを増加させる見込です。
上記に記載した新興国における医薬品市場は、2009〜2012年にかけて、14.7%の複合年間成長率で成長することが見込まれています。現在、これらの市場は、急速な都市化が特徴であり、その結果、生活習慣病の有病者数は増加しています。
新興7カ国において、中国は最大の医薬品市場であり、ブラジル、メキシコ、インドがそれに続きます。しかし、将来の最大成長は、政府の強力な援助により、ロシアと中国が見込まれています。さらに、新興7カ国の医薬品市場の大部分は、依然として急性期治療が中心ですが、慢性期治療の成長率は、急性期治療の成長率を上回ります。したがって、今後数年間の市場は、現在の実態とは大きく異なるでしょう。
本レポートは、新興国における医薬品市場について、広範かつ明解な情報を提供します。新興7カ国の医薬品市場の発展に沿って、さまざまなビジネスチャンスについても強調しました。また、人口動態、マクロ経済指数、疾患概説、市場の促進・抑制因子について、詳細な統計的および分析的レビューをもたらします。さらに本レポートは、このような新興医薬品市場において市場戦略を立案し、成功するためのビジネスチャンスが存在する分野を評価するのに役立ちます。
目次
- 1. Analyst View
- 2. Global Pharmaceutical Market
-
2.1 Market Size
2.2 Mature Markets - G7 Countries
2.3 Emerging Markets - E7 Countries
2.4 E7 Countries to Grow Strongly - 3. Why E7 Pharmaceutical Market?
-
3.1 Economic Growth
3.2 Income Level
3.3 Population Base
3.4 Prevalence of Lifestyle-related Diseases
3.5 Medical & Distribution Infrastructure
3.6 Health Insurance - 4. Industry Performance
-
4.1 Brazil (Past, Present & Future Scenario)
4.1.1 Macroeconomic Indicators
4.1.2 Population Profile
4.1.3 Disease Profile
4.1.4 Healthcare Spending & Financing
4.1.5 Pharmaceutical Market
4.1.6 Import & Export
4.1.7 Generic Drugs
4.1.8 Therapy Areas
4.1.9 Key Players
4.2 Russia (Past, Present & Future Scenario)
4.2.1 Macroeconomic Indicators
4.2.2 Population Profile
4.2.3 Disease Profile
4.2.4 Healthcare Spending & Financing
4.2.5 Pharmaceutical Market
4.2.6 Import
4.2.7 Branded & Generic Drugs
4.2.8 Key Players
4.3 India (Past, Present & Future Scenario)
4.3.1 Macroeconomic Indicators
4.3.2 Population Profile
4.3.3 Disease Profile
4.3.4 Healthcare Spending & Financing
4.3.5 Pharmaceutical Market
4.3.6 Import & Export
4.3.7 Branded & Generic Drugs
4.3.8 Therapy Areas
4.3.9 Key Players
4.4 China (Past, Present & Future Scenario)
4.4.1 Macroeconomic Indicators
4.4.2 Population Profile
4.4.3 Disease Profile
4.4.4 Healthcare Spending & Financing
4.4.5 Pharmaceutical Market
4.4.6 Import & Export
4.4.7 Branded & Generic Drugs
4.4.8 Therapy Areas
4.4.9 Key Players
4.5 Turkey (Past, Present & Future Scenario)
4.5.1 Macroeconomic Indicators
4.5.2 Population Profile
4.5.3 Disease Profile
4.5.4 Healthcare Spending & Financing
4.5.5 Pharmaceutical Market
4.5.6 Import & Export
4.5.7 Branded & Generic Drugs
4.5.8 Therapy Areas
4.5.9 Key Players
4.6 Mexico (Past, Present & Future Scenario)
4.6.1 Macroeconomic Indicators
4.6.2 Population Profile
4.6.3 Disease Profile
4.6.4 Healthcare Spending & Financing
4.6.5 Pharmaceutical Market
4.6.6 Import & Export
4.6.7 Branded & Generic Drugs
4.6.8 Therapy Areas
4.6.9 Key Players
4.7 Indonesia (Past, Present & Future Scenario)
4.7.1 Macroeconomic Indicators
4.7.2 Population Profile
4.7.3 Disease Profile
4.7.4 Healthcare Spending & Financing
4.7.5 Pharmaceutical Market
4.7.6 Import & Export
4.7.7 Branded & Generic Drugs
4.7.8 Key Players - 5. Opportunities
-
5.1 Chronic Diseases
5.2 Pharma Outsourcing Market
5.3 Vaccine Market
5.4 Medical Devices Market - 6. Restraining Forces
-
6.1 Counterfeit Drugs
6.2 Patent Protection
6.3 Traditional Medicines - 7. Key Players
-
7.1 GlaxoSmithKline
7.2 Sanofi-Aventis
7.3 Pfizer Inc.
7.4 Novartis
7.5 AstraZeneca
List of Figures:
Figure 2-1: Global - Pharmaceutical Market (Billion US$), 2005-2008
Figure 2-2: Global - Forecast for Pharmaceutical Market (Billion US$), 2009-2012
Figure 2-3: G7 Countries - Pharmaceutical Market (Billion US$), 2008
Figure 2-4: G7 Countries - Forecast for Pharmaceutical Market (Billion US$), 2012
Figure 2-5: G7 Countries - Forecast for Growth of Pharmaceutical Market (%), 2009 to 2012
Figure 2-6: E7 Countries - Pharmaceutical Market (Billion US$), 2008
Figure 2-7: E7 Countries - Forecast for Pharmaceutical Market (Billion US$), 2012
Figure 2-8: E7 Countries - Forecast for Growth of Pharmaceutical Market (%), 2009 to 2012
Figure 2-9: Global - Share of E7 & G7 Countries in Pharmaceutical Market (2008 & 2012)
Figure 3-1: G7 Countries - Real GDP (Trillion US$), 2004 & 2012
Figure 3-2: E7 Countries - Real GDP (Trillion US$), 2004 & 2012
Figure 3-3: Global - Share of E7 & G7 Countries in Population (2007 & 2012)
Figure 3-4: Relative Per Capita Spending on Drugs by Age Group
Figure 4-1: Brazil - Nominal GDP (Billion US$), 2007-2012
Figure 4-2: Brazil - Consumer Price Index (%), 2007-2012
Figure 4-3: Brazil - Currency Exchange Rate (From US$ to BRL), 2007-2012
Figure 4-4: Brazil - Foreign Direct Investment (Billion US$), 2005-2008
Figure 4-5: Brazil - Population (Million), 2006-2012
Figure 4-6: Brazil - Breakup of Population by Age Group (%), 2006-2012
Figure 4-7: Brazil - Population in the Age Group of 65 Years & Above (Million), 2006-2012
Figure 4-8: Brazil - Number of Deaths due to Leading Causes ('000)
Figure 4-9: Brazil - Breakup of Deaths by Various Causes (%), 2008
Figure 4-10: Brazil - Per Head Healthcare Spending (US$), 2006-2012
Figure 4-11: Brazil - Breakup of Healthcare Payment by Source (%), 2008
Figure 4-12: Brazil - Pharmaceutical Market (Billion US$), 2007-2012
Figure 4-13: Brazil - Pharmaceutical Imports (Billion US$), 2005-2008
Figure 4-14: Brazil - Pharmaceutical Exports (Million US$), 2005-2008
Figure 4-15: Brazil - Generic Drugs Market (Million US$), 2006-2012
Figure 4-16: Brazil - Share of Generic Drugs in Pharmaceutical Market (2008 & 2012)
Figure 4-17: Brazil - Pharmaceutical Market by Segment (%), 2008
Figure 4-18: Russia - Nominal GDP (Billion US$), 2007-2012
Figure 4-19: Russia - Consumer Price Index (%), 2007-2012
Figure 4-20: Russia - Foreign Direct Investment (Billion US$), 2005-2008
Figure 4-21: Russia - Population (Million), 2007-2012
Figure 4-22: Russia - Breakup of Population by Age Group (%), 2007-2012
Figure 4-23: Russia - Population in the Age Group of 65 Years & Above (Million), 2007-2012
Figure 4-24: Russia - Number of Deaths due to Leading Causes ('000)
Figure 4-25: Russia - Breakup of Deaths by Various Causes (%), 2008
Figure 4-26: Russia - Per Head Healthcare Spending (US$), 2006-2012
Figure 4-27: Russia - Breakup of Healthcare Payment by Source (%), 2008
Figure 4-28: Russia - Pharmaceutical Market (Billion Rubles), 2007-2012
Figure 4-29: Russia - Pharmaceutical Imports (Billion Rubles), 2007 & 2008
Figure 4-30: Russia - Share of Branded & Generic Drugs in Pharmaceutical Market (2008)
Figure 4-31: India - Nominal GDP (Billion US$), 2007-2012
Figure 4-32: India - Consumer Price Index (%), 2007-2012
Figure 4-33: India - Foreign Direct Investment (Billion US$), 2006-07 to 2008-09
Figure 4-34: India - Foreign Direct Investment in Pharmaceutical Market (Million US$), 2006-07 to 2008-09
Figure 4-35: India - Population (Million), 2006-2012
Figure 4-36: India - Breakup of Population by Age Group (%), 2006-2012
Figure 4-37: India - Population in the Age Group of 65 Years & Above (Million), 2006-2012
Figure 4-38: India - Number of Deaths due to Leading Causes ('000)
Figure 4-39: India - Breakup of Deaths by Various Causes (%), 2008
Figure 4-40: India - Per Head Healthcare Spending (US$), 2006-2012
Figure 4-41: India - Breakup of Healthcare Payment by Source (%), 2006
Figure 4-42: India - Pharmaceutical Market (Billion INR), 2006-07 to 2012-13
Figure 4-43: India - Pharmaceutical Imports (Billion INR), 2006-07 to 2012-13
Figure 4-44: India - Pharmaceutical Exports (Billion INR), 2006-07 to 2012-13
Figure 4-45: India - Forecast for Breakup of Domestic Pharmaceutical Market by Segment (%), 2010
Figure 4-46: China - Nominal GDP (Billion US$), 2007-2012
Figure 4-47: China - Consumer Price Index (%), 2007-2012
Figure 4-48: China - Foreign Direct Investment (Billion US$), 2005-2008
Figure 4-49: China - Population (Million), 2007-2012
Figure 4-50: China - Breakup of Population by Age Group (%), 2007-2012
Figure 4-51: China - Population in the Age Group of 65 Years & Above (Million), 2007-2012
Figure 4-52: China - Number of Deaths due to Leading Causes ('000)
Figure 4-53: China - Breakup of Deaths by Various Causes (%), 2008
Figure 4-54: China - Per Head Healthcare Spending (US$), 2006-2012
Figure 4-55: China - Breakup of Healthcare Payment by Source (%), 2006
Figure 4-56: China - Pharmaceutical Market (Billion US$), 2007-2012
Figure 4-57: China - TCM Market (Billion CNY), 2005-2008
Figure 4-58: China - Pharmaceutical Purchase by Source (%)
Figure 4-59: China - Medicine & Health Product Imports (Billion US$), 2005-2007
Figure 4-60: China - Breakup of Medicine & Health Product Imports by Type (%), 2006
Figure 4-61: China - Medicine & Health Product Exports (Billion US$), 2005-2007
Figure 4-62: China - Breakup of Medicine & Health Product Exports by Type (%), 2006
Figure 4-63: China - Pharmaceutical Market by Type of Drug (%), 2007
Figure 4-64: Turkey - Nominal GDP (Billion US$), 2007-2012
Figure 4-65: Turkey - Consumer Price Index (%), 2007-2012
Figure 4-66: Turkey - Foreign Direct Investment (Billion US$), 2006-2008
Figure 4-67: Turkey - Population (Million), 2006-2012
Figure 4-68: Turkey - Breakup of Population by Age Group (%), 2006-2012
Figure 4-69: Turkey - Population in the Age Group of 65 Years & Above (Million), 2006-2012
Figure 4-70: Turkey - Number of Deaths due to Leading Causes ('000)
Figure 4-71: Turkey - Breakup of Deaths by Various Causes (%), 2008
Figure 4-72: Turkey - Per Head Healthcare Spending (US$), 2006-2012
Figure 4-73: Turkey - Breakup of Healthcare Payment by Source (%)
Figure 4-74: Turkey - Pharmaceutical Market (Billion US$), 2007-2012
Figure 4-75: Turkey - Pharmaceutical Market (Million Boxes), 2006-2008
Figure 4-76: Turkey - Share of Imported & Domestically Manufactured Drugs in Pharmaceutical Market (2008)
Figure 4-77: Turkey - Pharmaceutical Exports (Million US$), 2006-2008
Figure 4-78: Turkey - Share of Branded & Generic Drugs in Pharmaceutical Market (2008)
Figure 4-79: Turkey - Share of Branded & Generic Drugs Sales Volume in Pharmaceutical Market (2008)
Figure 4-80: Mexico - Nominal GDP (Billion US$), 2007-2012
Figure 4-81: Mexico - Consumer Price Index (%), 2007-2012
Figure 4-82: Mexico - Foreign Direct Investment (Billion US$), 2006-2008
Figure 4-83: Mexico - Population (Million), 2006-2012
Figure 4-84: Mexico - Breakup of Population by Age Group (%), 2006-2012
Figure 4-85: Mexico - Population in the Age Group of 65 Years & Above (Million), 2006-2012
Figure 4-86: Mexico - Number of Deaths due to Leading Causes ('000)
Figure 4-87: Mexico - Breakup of Deaths by Various Causes (%), 2008
Figure 4-88: Mexico - Per Head Healthcare Spending (US$), 2006-2012
Figure 4-89: Mexico - Breakup of Healthcare Payment by Source (%)
Figure 4-90: Mexico - Pharmaceutical Market (Billion US$), 2007-2012
Figure 4-91: Mexico - Pharmaceutical Imports (Billion US$), 2003 & 2007
Figure 4-92: Mexico - Pharmaceutical Exports (Billion US$), 2003, 2006 & 2007
Figure 4-93: Mexico - Share of Branded & Generic Drugs in Pharmaceutical Market (2008)
Figure 4-94: Mexico - Share of Top Players in Pharmaceutical Market (2007)
Figure 4-95: Indonesia - Nominal GDP (Billion US$), 2007-2012
Figure 4-96: Indonesia - Consumer Price Index (%), 2007-2012
Figure 4-97: Indonesia - Foreign Direct Investment (Billion US$), 2006-2008
Figure 4-98: Indonesia - Population (Million), 2007-2012
Figure 4-99: Indonesia - Breakup of Population by Age Group (%), 2007-2012
Figure 4-100: Indonesia - Population in the Age Group of 65 Years & Above (Million), 2007-2012
Figure 4-101: Indonesia - Number of Deaths due to Leading Causes ('000), 2005
Figure 4-102: Indonesia - Breakup of Deaths by Various Causes (%), 2008
Figure 4-103: Indonesia - Per Head Healthcare Spending (US$), 2006-2012
Figure 4-104: Indonesia - Breakup of Healthcare Payment by Source (%), 2008
Figure 4-105: Indonesia - Pharmaceutical Market (Trillion Rp), 2007-2012
Figure 4-106: Indonesia - Share of OTC & Prescription Drugs in Pharmaceutical Market (2008)
Figure 4-107: Indonesia - Pharmaceutical Exports (Million US$) 2004-2007
Figure 4-108: Indonesia - Pharmaceutical Imports (Million US$) 2004-2007
Figure 4-109: Indonesia - Share of Branded & Generic Drugs in Pharmaceutical Market (2008)
Figure 4-110: Indonesia - Share of Top Players in Prescription Pharmaceutical Market (Q1 2009)
Figure 4-111: Indonesia - Share of Top Players in OTC Pharmaceutical Market (Q1 2009)
Figure 5-1: Global - Pharma Outsourcing Market by Segment (%), 2006
Figure 5-2: BRIC Countries - Medical Device Market (Million US$), 2006
List of Tables:
Table 2-1: Global - Pharmaceutical Market by Region (Billion US$), 2008
Table 3-1: E7 Countries - Disposable Income (Million US$), 2007 & 2012
Table 3-2: G7 Countries - Population (Million), 2007 & 2012
Table 3-3: E7 Countries - Population (Million), 2007 & 2012
Table 3-4: G7 Countries - Population in the Age Group of 65 Years & Above (Million), 2007 & 2012
Table 3-5: E7 Countries - Population in the Age Group of 65 Years & Above (Million), 2007 & 2012
Table 4-1: Brazil - Performance of Top 10 Players in Pharmaceutical Market (2006)
Table 4-2: Russia - Performance of Key Players in Pharmaceutical Market (2008)
Table 4-3: India - Performance of Drugs by Therapeutic Segment in Domestic Pharmaceutical Market
Table 4-4: India - Performance of Top 10 Pharmaceutical Players (2008)
Table 4-5: China - Performance of Drugs by Key Therapeutic Segment in Pharmaceutical Market (2005 & 2006)
Table 4-6: China - Performance of Key Players in Pharmaceutical Market (H1 2006 & H1 2007)
Table 4-7: Turkey - Performance of Key Therapy Areas in Pharmaceutical Market (2008)
Table 4-8: Turkey - Top 20 Pharmaceutical Players by Sales (Million US$), Jan-Sep 2007
Table 4-9: Turkey - Top 20 Pharmaceutical Players by Sales Volume (Million Units), Jan-Sep 2007
Table 4-10: Mexico - Performance of Therapy Areas in Retail Pharmaceutical Market (2006)
Table 5-1: India - Market for Various Chronic Diseases (Billion INR), 2006 & 2010
Table 5-2: India, China & Brazil - Vaccine Market (Million US$), 2006 & 2010
Table 7-1: GlaxoSmithKline plc - Strengths & Weaknesses
Table 7-2: Sanofi-Aventis - Strengths & Weaknesses
Table 7-3: Pfizer Inc - Strengths & Weaknesses
Table 7-4: Novartis - Strengths & Weaknesses
Table 7-5: AstraZeneca - Strengths & Weaknesses
発刊日
2009/12/01
体裁
PDF / 130ページ
販売価格
1,500USD
発行
RNCOS
備考
※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。
